$20M Milestone Payment: What It Means for Keros Therapeutics' Ambitious Plans The biotech sector has long been plagued by tales of failed trials, bankrupted companies, and promises unfulfilled.
But when Keros Therapeutics, Inc.
(NASDAQ:KROS) recently triggered a $20 million development milestone payment from Takeda Pharmaceutical Company Limited (NYSE:TAK), investors took notice – and the company's stock price soared.